Opening book details…
About this Medicine article
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08 by Zaman, Khalil; Winterhalder, Ralph; Mamot, Christoph; Hasler-Strub, Ursula; Rochlitz, Christoph; Mueller, Andreas; Berset, Catherine; Wiliders, Hans; Perey, Lucien; Rudolf, Christine Biaggi; Hawle, Hanne; Rondeau, Stephanie; Neven, Patrick is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Zaman, Khalil; Winterhalder, Ralph; Mamot, Christoph; Hasler-Strub, Ursula; Rochlitz, Christoph; Mueller, Andreas; Berset, Catherine; Wiliders, Hans; Perey, Lucien; Rudolf, Christine Biaggi; Hawle, Hanne; Rondeau, Stephanie; Neven, Patrick
- Publisher
- Elsevier Science; Elsevier ; Elsevier Ltd.; Elsevier BV (ISSN 0959-8049)
- Published
- 2015
- Language
- EN
- Field
- Medicine (Health Sciences)